CCC07-01
Modify Date: 2024-06-09 21:00:56
CCC07-01 structure
|
Common Name | CCC07-01 | ||
|---|---|---|---|---|
| CAS Number | 2215102-35-3 | Molecular Weight | 1886.378 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C90H93ClN30O16 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CCC07-01CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays; significantly suppresses PD-1, PD-L1 and CTLA-4 mRNA levels in several cell lines, CCC07-01 is sufficiently lipophilic that enhaced the inhibitory effect of CD94-NKG-2A receptor expressed on subsets of NK cells γδ and CD8+ T cells. |
| Name | CCC07-01 |
|---|
| Description | CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays; significantly suppresses PD-1, PD-L1 and CTLA-4 mRNA levels in several cell lines, CCC07-01 is sufficiently lipophilic that enhaced the inhibitory effect of CD94-NKG-2A receptor expressed on subsets of NK cells γδ and CD8+ T cells. |
|---|---|
| References | References 1. US Patent WO 2018056361. 2. Horiki Nagase, et al. 2018 AACR #2711: Development of a new innovative multifunctional immune checkpoint inhibitor. View Related Products by Target PD-1/PD-L1 |
| Molecular Formula | C90H93ClN30O16 |
|---|---|
| Molecular Weight | 1886.378 |